WATCH: @UroCroll of @FoxChaseCancer discusses the present and potential future standing of biomarkers in RCC. #kcsm #oncology #AUA26
hubs.li/Q04lCPRG0
185
Massage in
riyadh
jeddah
buraydah
al khaj
🐰🧉♂️🥔Morocco wa.me/ 966591748716
khobar
hofuf
dammam
abha
jubail
tabuk
massage at home riyadh,jeddah
kCSm
4
Jun 15
WATCH: @UroCroll of @FoxChaseCancer discusses research focused on understanding response to systemic therapy in RCC. #oncology #RCC #kcsm
hubs.li/Q04lvcv00
1
259
Jun 15
The combination of cadonilimab plus axitinib demonstrated promising efficacy and a manageable safety profile as frontline therapy for advanced non–clear cell RCC.
Read more ➡️ hubs.li/Q04lq4Xl0
#KidneyCancer #RCC #nccRCC #GUonc #Immunotherapy #kcsm #TargetedTherapy #PrecisionOncology #Oncology #MedTwitter
292
Funky Friday Radio Show Ep 72: Freedom
From The Isley Brothers and Curtis Mayfield to Parliament, Earth, Wind & Fire, and Stevie Wonder.
Episode 72 arrives June 19.
KDOG 9am PT.
KCSM HD2 9pm PT.
Links in bio/comments.
#FunkMusic #Juneteenth #KCSM #KDOG
18
Jun 12
BREAKING 🚨: @FDAOncology Approves Adjuvant Belzutifan Plus Pembrolizumab in RCC
Learn more about the data supporting this regulatory decision 📰➡️ onclive.com/view/fda-approve…
#FDAapproved #kcsm #oncology
298
Jun 12
🚨 The FDA has approved adjuvant belzutifan plus pembrolizumab for patients with ccRCC who have an intermediate or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.
hubs.li/Q04ldVTj0
#kcsm #oncology #cancer | @ASCO
103
Research Log 071.
Formula 71 has entered active testing.
The groove cannot be contained.
Acid Funk.
Tomorrow.
KDOG 9am PT
KCSM HD2 9pm PT
#KCSM #KDOG #RenegadeChronicles #FunkyFriday
7
Jun 10
I may live in the UK, but I do very much enjoy KCSM on the internet, fine jazz radio.
kcsm.org/
3
109
Jun 10
📢 ¡Nueva edición de @ProjectECHO en Tumores GU!
🌎 El conocimiento necesita viajar. Los pacientes NO
📅 12 de junio
🕗 08:00 hs
💻 Modalidad virtual iECHO.org
"Moviendo conocimiento y no pacientes"
#EducaciónMédica #Blcsm #Pcasm #KCsm #GermTumor #GUOncology
1
1
3
129
Research Log 071:
Formula 71 has entered active testing.
Bass.
Wah.
Groove.
Funky Friday Episode 71: Acid Funk
Fri 6.12.26
KDOG 9am PT
KCSM HD2 9pm PT
renegadechronicles.com/post/…
9
College of San Mateo extends its sincere gratitude to everyone who joined us last Saturday for KCSM Jazz on the Hill 2026.
#CollegeOfSanMateo #JazzOnTheHill #KCSM
instagram.com/p/DZYtpPrGWeZ/…
37
May 30
🏥 #ASCO26 update in kidney cancer:
Adjuvant durvalumab tremelimumab demonstrated a disease-free survival advantage vs active monitoring in patients with resected RCC, although durvalumab monotherapy did not. @asco #RCC #kcsm #oncology #medtwitter
Read more here: onclive.com/view/adjuvant-du…
2
3
307
May 30
Excellent study by @BethN01 & the team at @QMBCI with an outstanding discussion by @brian_rini. I hope the first of many such studies across various cancers! #kcsm #ASCO26
@tompowles1 @Uromigos @scocmem @nataliagandur @OncoAlert @KidneyCancer @KidneyCancer @RCCadvocate
May 30
A Great Start to Day Two of #ASCO26 and no better way to start than our @OncoAlert 🚨from the Podium to your feed with Dr. Elizabeth Nally from Barts Cancer institute🇬🇧 discussing Abstract 4512 : Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.
In this multicentre London study of 104 patients with RCC treated with adjuvant pembrolizumab, decision regret was uncommon (13%) after a median 30-month follow-up. Regret was driven primarily by long-term, patient-perceived significant or life-changing toxicities rather than disease recurrence or CTCAE-graded severity. Permanent endocrine and musculoskeletal toxicities were associated with the highest regret.
Patient-informed toxicity assessments outperformed CTCAE criteria in identifying regret, highlighting the importance of patient education and shared decision-making. #KidneyCancer
Elizabeth Nally
@veda13k @scocmem @b_szabados @Naveed_Sarwar @tompowles1 @montypal @crisbergerot
Pinging OncoAlert Faculty
@brian_rini 🇺🇸@declangmurphy 🇦🇺 @KidneyCancer 🇺🇸 @salvolarosa @silkegillessen🇨🇭 @APCCC_Lugano @RenuEapen 🇦🇺 @nataliagandur 🇦🇷 @seanmcbride 🇺🇸 @DrJaVallejo 🇪🇸 Pinging our ASCO Pulse Faculty @DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @CathyEngMD 🇺🇸 @stolaney1 🇺🇸 @montypal 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim 🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago 🇪🇸 @DrMirallas 🇺🇸 @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸
7
14
1,469
May 29
Abstr. 4500. RADICAL/A031801: Does adding Radium-223 to cabo in pts with RCC symptomatic bone mets improve SSE-free survival (SSE-FS)?
Median SSE-FS 17.9 vs 17.6 mo. ORR ~22% in both arms. PFS 11.0 vs 11.2 mo. Trial stopped early for futility. Radium-223 cabo did not improve SSE-FS vs cabo alone.
Implications: In RCC bone mets, bone-seeking radioligands may be insufficient. CAIX-targeted radioligand therapies in combination /- TKI-IO therapy may be more promising ➡️ongoing STARLITE-1, STARLITE-2, & LUTEON trials examining ¹⁷⁷Lu-girentuximab (TLX250), a CAIX-targeted radioligand, in various advanced ccRCC settings.
Congratulations to @DrRanaMcKay, the study team, & @ALLIANCE on their perseverance in conducting this trial. @OncoAlert @KidneyCancer @kidneycan @scocmem @nataliagandur #kcsm #ASCO26
8
12
1,180
May 29
WATCH 👀: Benjamin Croll, MD, of @FoxChaseCancer discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.
See the whole video here ➡️: hubs.li/Q04jjMT-0
#kcsm #oncology
1
3
248
May 28
A really thought-provoking study at #ASCO26 (Abstr 4512, Clinical Science Symposium): decision regret after adjuvant pembrolizumab in RCC.
🔹 The question
Do patients regret receiving adjuvant pembro — and if so, is it driven by long-term toxicity that CTCAE grading doesn't adequately reflect? They built a patient co-designed tool focused on long-term toxicity.
🔹 The study
104 RCC pts post-adjuvant pembro across 3 London centres, median f/u 30 mo. Pts completed the Ottawa Decision Regret Scale alongside their own rating of irAEs as life-changing, significant, or non-significant.
🔹 What they found
28% rated their toxicity as significant and 11% as life-changing — but these ratings did NOT correlate with CTCAE grade (a third of G1–2 events were rated significant), and regret was identical for G1–2 vs G3–4 irAEs. Regret was driven by patient-perceived long-term toxicity, especially permanent endocrine and MSK irAEs — and not by disease recurrence (only 1/14 who relapsed expressed regret). Lower baseline expectations of toxicity → more regret.
🔹 My take
Striking that >1 in 4 reported significant and >1 in 10 life-changing toxicity. What concerns me most isn't that CTCAE missed these events — it's that the grade didn't correlate with how significant patients found them, nor with regret at all. That deviates from the very purpose of grading. The hard part: a regret analysis is tough to contextualize when the alternative, no treatment, risks recurrence — arguably worse than a long-term toxicity. Adjuvant therapy is challenging by nature: most patients are either cured already or destined to recur regardless — we expose everyone to toxicity to benefit a minority. We urgently need biomarkers to find the few who truly benefit. This slide from @Prof_IanD says it all 👇
Looking forward to seeing the presentation!
🔗 asco.org/abstracts-presentat…
#kcsm #ASCO26
@BethN01 @tompowles1
5
30
95
22,362
May 27
Thomas Powles, MBBS, MRCP, MD, Brian Rini, MD, FASCO, and Elizabeth Plimack, MD, MS, FASCO, tackle first-line decision-making in advanced RCC, from tumor biology and IMDC risk stratification to emerging therapies and dose optimization in this 13-episode OncLive News Network series.
Watch now: hubs.li/Q04dqmQf0
#RenalCellCarcinoma #kcsm #Oncology @tompowles1 @NHSBartsHealth @brian_rini @VUMChealth @ERPlimackMD @FoxChaseCancer
5
7
520